ARCHIVES

NCIs FY95 Bypass To Justify $3.47 Billion, includes $490 million For Breast Cancer Research

This article is from The Cancer Letter archive.

Vol. 19 No. 20 | May 14, 1993

Download PDF Visit The Full Archive

Related Articles

J&J, Amgen Settle Lawsuit Over ESAs As FDA Prepares Another Label Change.

July 18, 2008

Celebrex Studies Show Polyp Reduction, Point To Challenges In Biomarker Validation

April 28, 2006

Deals and Collaborations: Firms Get First Payment From Bristol-Myers for Taxol

March 5, 1999

Medicare Cuts Proposed In budget reduction Amendment For FY94

November 19, 1993

Lenalidomide Found Effective For Lymphoma In Phase II Trial

December 26, 2008

Schmidt Approve NCAB Authorizations

February 18, 1977